Author

C. Keller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1 Immunology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. D. Gruber· 1 shared A. D. Woods· 1 shared A. Haider· 1 shared A. Meisel· 1 shared A. Nist· 1 shared A. Portmann· 1 shared A. Rossi· 1 shared A. Warth· 1 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. D. Gruber

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

High-resolution epigenetic profiling identifies novel regulators of COPD in human lung fibroblasts

U. Schwartz, M. Llamazares Prada, S. T. Pohl, M. Richter, R. Tamas, M. Schuler, C. Keller, V. Mijosek, T. Muley, M. A. Schneider, K. Quast, J. Hey, C. P. Heussel, A. Warth, H. Winter, , R. Jurkowska

This study identifies novel epigenetic and transcriptomic regulators of COPD in human lung fibroblasts across disease stages.

bioRxiv · Mar 28, 2022 · PreprintCell Biology

Single cell RNA-seq uncovers the nuclear decoy lincRNA PIRAT as a regulator of systemic monocyte immunity during COVID-19

M. Aznaourova, N. Schmerer, H. Janga, Z. Zhang, K. Pauck, J. Hoppe, S. M. Volkers, D. Wendisch, P. Georg, M. Guendisch, E. Mack, C. Skevaki, C. Keller, C. Bauer, W. Bertrams, , L. N. Schulte

The paper identifies PIRAT, a lncRNA regulating monocyte immunity in COVID-19 via PU.1 feedback, and shows its role in alarmin production.

bioRxiv · Nov 5, 2021 · PreprintImmunology

Rest/Stress Myocardial Perfusion Imaging by Positron Emission Tomography with 18F-Flurpiridaz: A Feasibility Study in Mice

S. Bengs, G. I. Warnock, A. Portmann, N. Mikail, A. Rossi, H. Ahmed, D. Etter, L. Gisler, C. Jie, A. Meisel, C. Keller, R. Schibli, L. Mu, R. R. Buechel, P. A. Kaufmann, , A. Haider

This study evaluates the feasibility of rest/stress PET-MPI with 18F-flurpiridaz in mice, finding that myocardial uptake correlates with perfusion parameters and enables CFR estimation.

bioRxiv · Sep 5, 2021Physiology

Bromodomain 4 inhibition leads to MYCN downregulation in Wilms' tumor cells

A. D. Woods, C. Keller, N. E. Berlow, J. E. Michalek, B. Royer-Pokora, R. Purohit, K. E. Tranbarger Freier, M. Lathara, K. Matlock, G. Srivivasa, R. Veselska

This study shows that BRD4 inhibition reduces MYCN levels and suppresses proliferation in Wilms tumor cells, suggesting AZD5153 as a potential therapeutic agent.

bioRxiv · Jan 4, 2021 · PreprintCancer Biology

Efficacy of the MEK1/2 inhibitor trametinib in combination with clinically-investigated γ-secretase inhibitors in rhabdomyosarcoma

M. Cleary, D. S. Hawkins, C. Keller

This study tests the efficacy of trametinib and gamma-secretase inhibitors in RMS cell lines, finding no significant effect on cell viability when combined.

bioRxiv · Apr 29, 2019 · PreprintCancer Biology